Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited's subsidiary, Biocon Biologics, has expanded its existing in-licensing agreement with FKB (Fujifilm Kyowa Kirin Biologics) to gain full worldwide rights for the biosimilar version of Adalimumab, a key immunology drug used to treat conditions like rheumatoid arthritis. This move upgrades the arrangement from a regional or limited scope to a complete global commercial rights agreement, allowing Biocon Biologics to market and distribute the product across all major markets independently. Adalimumab is a high-value biosimilar, and full global rights strengthen Biocon Biologics' international biosimilars portfolio. The press release was formally shared with the stock exchange for disclosure purposes.
Positive for Biocon shareholders — securing full global rights enhances revenue potential and strategic control over a major biosimilar asset, likely supporting long-term growth for the biologics business. No immediate impact on share price from this disclosure alone, but strengthens the company's competitive positioning in the global biosimilars market.